What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “RXC007 will be administered in the form of oral capsules at 3 potential dose levels: 20 mg, 50mg and 70 mg in 5 cohorts. 12 patients of cohorts 1, 2 and the Expansion cohort will receive RXC007. The Dosage regimen is BID or QD.”In the company’s words, NCT05570058 on ClinicalTrials.gov
- Main trialPhase 2
- “The purpose of the study is to assess the safety and tolerability of RXC007 when given for 12 weeks (84 days), alone and in combination with nintedanib or pirfenidone.”In the company’s words, NCT05570058 on ClinicalTrials.gov
Other drugs for IPF
- SC1011JOYO Pharma · Phase 2/3
- NerandomilastBoehringer Ingelheim · Phase 3
- NAL ERTrevi Therapeutics · Phase 3
- AK3280Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 3
- TDI01Beijing Tide Pharmaceutical Co., Ltd · Phase 3
- INS018_055InSilico Medicine Hong Kong Limited · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 25 Jun 2024 | Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis | |
| Phase 1Completed | 8 Mar 2023 | A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026